According to a report from Zhito Finance APP, Apichope Pharmaceutical (300723.SZ) announced that the company's board of directors agreed to the company's controlling subsidiary, Guangdong South China Vaccine Co., Ltd. (referred to as "South China Vaccine") signing the "Flu Recombinant Protein Vaccine Project Patent and Technology Transfer Agreement" (referred to as the "Agreement") with Zhuhai Lizhu Monoclonal Biotechnology Co., Ltd. (referred to as "Lizhu Monoclonal"). According to the Agreement, South China Vaccine intends to transfer the project rights of the trivalent flu recombinant protein vaccine and/or quadrivalent flu recombinant protein vaccine, which is the final sales form based on the project technology development, to Lizhu Monoclonal. The total amount of this trade is 0.21 billion yuan, which includes a down payment of 5 million yuan and milestone payments totaling 20.5 million yuan. After product commercialization, it has the right to receive a commission based on sales, totaling no more than 2 billion yuan.